{
    "2021-02-17": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Vir and GSK Will Collaborate on Flu Therapy",
                "features": {
                    "keywords": [
                        "Vir",
                        "GSK",
                        "Collaborate",
                        "Flu Therapy"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Eli Lilly's Tirzepatide Reduces A1C And Body Weight, Late-Stage Studies In Type 2 Diabetes Show",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Tirzepatide",
                        "A1C",
                        "Body Weight",
                        "Type 2 Diabetes"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program",
                "features": {
                    "keywords": [
                        "Tirzepatide",
                        "A1C",
                        "Body Weight",
                        "Type 2 Diabetes",
                        "Phase 3 Trials",
                        "SURPASS Program"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Kimberly H. Johnson Elected to Lilly Board of Directors",
                "features": {
                    "keywords": [
                        "Kimberly H. Johnson",
                        "Lilly",
                        "Board of Directors"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "corporate governance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}